Hans-Juergen Martin

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Ajinomoto Co., Ltd.. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Juergen Martin. Retrieved from https://idiyas.com/inventor/hans-juergen-martin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 87.5

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 5.3

ph-index = 5

Forward Citations = 140(Granted Patents)

Location History:

Biberach, DE (2009 - 2013)
Biberach an der Riss, DE (2014 - 2015)

Company Filing History:

7 out of 1,562

Boehringer Ingelheim International Gmbh

where one patent can have more than one assignee

Years Active: 2009-2015

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9145434 - Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments (2015-09-29),

2. 9120769 - Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline (2015-09-01),

3. 8686149 - Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline (2014-04-01),

4. 8507450 - Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments (2013-08-13),

5. 8283326 - Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments (2012-10-09),

6. 7838500 - Crystalline form of 1'-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments (2010-11-23),

7. 7723309 - [object Object] (2010-05-25),

8. 7524822 - Crystalline form of 1'-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments (2009-04-28),

Title: The Innovative Contributions of Hans-Juergen Martin

Introduction

Hans-Juergen Martin is a notable inventor based in Biberach, Germany. He has made significant contributions to the field of pharmacology, holding a total of eight patents. His work focuses on the development of compounds that have valuable pharmacological activities.

Latest Patents

Among his latest patents is a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene. This invention relates to methods for its preparation and its use in preparing medicaments. Another significant patent involves aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline. These compounds are defined by specific formulas and possess valuable pharmacological activity, particularly as inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1. This makes them suitable for the treatment and prevention of diseases influenced by this enzyme, such as type 2 diabetes, obesity, and dyslipidemia.

Career Highlights

Hans-Juergen Martin has worked with prominent companies in the pharmaceutical industry, including Boehringer Ingelheim International GmbH and Ajinomoto Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative medicinal compounds.

Collaborations

Throughout his career, he has collaborated with notable colleagues such as Matthias Eckhardt and Frank Himmelsbach. These partnerships have likely enhanced his research and development efforts in the field of pharmacology.

Conclusion

Hans-Juergen Martin's contributions to the field of pharmacology through his innovative patents and collaborations highlight his significant role as an inventor. His work continues to influence the development of new medicaments that address critical health issues.

Profile summary based on public USPTO records.